Wednesday, June 26

9:40 AM – 9:55 AM | Advancing Nanobiomechanical Research: Large Tissue Area Mapping and Nano Scale Rheology via AFM

Sponsored by Bruker
Location: Hall 4A
Speaker: Yi Wei

The expansion of atomic force microscopy (AFM) applications to encompass nanomechanical measurements across millimeter to centimeter scales, coupled with the exploration of rheological properties in the frequency domain, introduces a complex array of challenges. The inherent precision and sensitivity of AFM, tailored for atomic and nanoscale interactions, are tested as we extend its scope. In a collaborative study with Prof. Dr. Thorsten Hugel (AFM) and Prof. Dr. Bernd Rolauffs (SCSO), we explore the nanomechanical landscape of osteoarthritis (OA) on a large tissue scale. Through a novel hybrid fluorescence-AFM approach, we successfully correlated superficial chondrocyte spatial organization (SCSO) with microscale elastic modulus and identified nanoscale mechanical property variations in articular cartilage (AC). This technique enabled the precise mapping of elastic modulus variations over extensive areas of native AC, unveiling pivotal insights into the early stages of OA. By elucidating the relationship between cellular organization and mechanical alterations in tissue, our findings offer a new lens through which to view the hierarchical structure of biological tissues such as cartilage.

12:30 PM – 12:50 PM | 20-Minute Satellite Session

Sponsored by: Phil and Penny Knight Campus for Accelerating Scientific Impact

1:00 PM – 1:20 PM | Unlock Half a Million in Funding: Tips to Win the Burroughs Wellcome Fund’s Innovations in Regulatory Science Award

Sponsored by: Burroughs Wellcome Fund
Speaker: Tammy Collins, Program Officer
Calling all researchers at TERMIS! Don’t miss this information session on the Burroughs Wellcome Fund’s Innovations in Regulatory Science Awards. Discover what it takes to secure up to $500K in research funding. Join us for a brief yet insightful overview where we’ll reveal exactly what BWF is looking for in award candidates. Elevate your research with insider tips and boost your chances of winning this prestigious grant!

4:50 PM – 5:05 PM | Medical innovation in 3D printing from nature’s toolbox

Sponsored by Viscofan
Location: Hall 4A

As a central structural protein, collagen provides strength and elasticity in all animal connective tissues. Nature has therefore retained the basic structure of this important building material over the course of evolution: A triple helix of three polypeptide strands with a firmly defined amino acid sequence. The cross-linking of these tau-like fibres forms a scaffold for cells in the body as a prerequisite for the formation and regeneration of tissue. Medicine uses collagen as a biomaterial for the treatment of damaged organs, e.g. as an implant membrane. The protein can be easily customised for different applications by manipulating its physical, chemical and biological properties. Collagen gel plays an important role as an ‘ink’ in the development of 3D printing processes in biomedicine for the production of matrices, tissue and organ models.
The Fibercoll-Flex® bioink family are collagen bioinks that do not require stabilisation with methacrylate curing. At an acidic pH (2.0 – 3.0), native collagen has a maximum gel viscosity with even distribution of the fibres and homogeneous flow properties. For 3D printing of self-supporting models, collagen type I fibres with a length of 200-800 µm and a diameter of 20 µm are used, which have optimal structural-viscous behaviour. The stability is influenced by the collagen concentration, among other things. After printing, living cells can grow into the carrier structure, which then serves as artificial tissue, e.g. for pharmaceutical screenings. With Fibercoll-Flex®-A, Viscofan has developed an acidic collagen gel for models with a viscosity between 2 – 10 kPa.
3D printing with cells leads directly to an ‘animated’ tissue model, but is a real challenge as the shear force can damage the sensitive membranes and printing requires physiological conditions (neutral pH, 37°C). With Fibercoll-Flex®-N, Viscofan offers a bio-ink that is pH-neutralised and mixed with living cells before use. Printing takes place at 20-37°C and produces models with a strength of 0.2 – 0.9 kPa.
As the FibercollFlex bioinks do not require cross-linking, the printed models are therefore particularly biocompatible and offer optimal conditions for cell adhesion and growth as ‘in vivo’-like carrier structures. As an innovative printing material for the production of tissue models, Fibercoll-Flex® collagen inks therefore have great potential for new applications in regenerative medicine.

6:25 PM – 6:40 PM | Accelerate Next-Gen Therapies, Personalized Medicine with 3D Bioprinted Hydrogels

Sponsored by: B9Creations
Speakers: B9Creations CEO Shon Anderon & Ronawk Co-Founder & CEO AJ Melott
Join us for an exciting presentation on the revolutionary Bio-Blocks® technology, developed by Ronawk and powered by B9Creations technology! Discover how Bio-Blocks® provide 3D micro-environments for cells to expand organically and continuously without subcultures, leading to high-quality tissue that can transform biological therapies, diagnostics, and research. Learn how this innovative approach overcomes the limitations of traditional plasticware and gel-based scaffolds, providing unparalleled support for cell growth and real-time analysis. Delve into the intricacies of 3D scaffolds, where the standard often falls short in precision and consistency. Explore how B9Creations’ cutting-edge technology is revolutionizing this field, offering unparalleled uniformity and reproducibility in 3D-printed Bio-Blocks®. Discover the game-changing advantages Ronawk harnesses through B9Creations’ capabilities and explore the future of tissue engineering and cell cultivation while hearing how B9Creations’ breakthrough platform accelerates drug discovery and the development of tailored therapies. Don’t miss this opportunity!

6:45 PM – 7:00 PM | Next-Generation Bioprinting (NGB) Platform: Leveraging the Capabilities for the Translation of Bioprinting Procedures to Clinic

Sponsored by: Scintica
Speakers: Niloufar Khosravi, PhD and Fabien Guillemot, PhD

To address the limitations of current tissue engineering methods and fulfill unmet clinical needs, the Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion. This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to clinic. The commercial NGB-R system is designed for developing bioprinting procedures at the preclinical stage that are translatable to the clinical-ready NGB-C system. This system complies with Good Manufacturing Practices (GMP) for Advanced Therapy Medicinal Products (ATMPs). In this presentation, we will showcase this translation capacity through our first bioprinted tissue therapeutics including skin and cartilage, that are being developed using the NGB platform.

7:05 PM – 7:20 PM | Macroporous Alginate Foam Scaffolds for 3D Cell Growth

Sponsored by: IFF
Speaker: Mark Dreibelbis, Senior Scientist

Biopolymer-based hydrogel scaffolds can serve as 3D cell growth environments which enable attachment and proliferation in a biologically meaningful environment. In this study, an alginate-based porous foam scaffold was produced through mechanical aeration and slow internal gelling followed by casting and drying for use as 3D cell culture scaffolds. Cell growth will be demonstrated in murine fibroblasts (NIH3T3) among other model cell types. Cells were immobilized within the foam hydrogel by in-situ gelation with either ultrapure (UP) alginate or UP alginate with coupled GRGDSP peptide sequence. Using fluorescence microscopy, cell proliferation and spheroid formation were observed across a range of cell densities and alginate concentrations, where both lower alginate density and lower cell seeding density encouraged NIH3T3 proliferation and reorganization into larger cell structures. Larger structures with elongated cell morphology were seen in peptide-coupled alginate conditions, where cell structures colocalized with foam scaffold pores. Alginate-based foam scaffolds can achieve consistent encapsulation of cells in a defined alginate network. Modulation of alginate concentration and peptide moieties influences cell response in these networks, where tailoring these properties can aid efforts in tissue engineering and therapeutic screening.

Thursday, June 27

9:40 AM – 9:55 AM | Combining Bioprinting, Microfabrication and Biomaterials to Create Advanced 3D Models

Sponsored by: Cellink

4:50 PM – 5:05 PM | BMAP® Knee: A Human-Scaled Knee Biomimetic Bioreactor for Patient-Specific Osteochondral Tissue Engineering

Sponsored by: Regemat3D

5:10 PM – 5:25 PM | Unlock Half a Million in Funding: Tips to Win the Burroughs Wellcome Fund’s Innovations in Regulatory Science Award

Sponsored by: Burroughs Wellcome Fund
Speaker: Tammy Collins, Program Officer
Calling all researchers at TERMIS! Don’t miss this information session on the Burroughs Wellcome Fund’s Innovations in Regulatory Science Awards. Discover what it takes to secure up to $500K in research funding. Join us for a brief yet insightful overview where we’ll reveal exactly what BWF is looking for in award candidates. Elevate your research with insider tips and boost your chances of winning this prestigious grant!

6:25 PM – 6:40 PM | Next-generation designer culture media for in vitro 2D/3D modeling and serum-free media engineered for clinical scenarios

Sponsored by CELLnTEC Advanced Cell Systems
Dr. Elias Imahorn, Scientist & QC Manager
Dr. Anand David, Scientific Marketing Manager

CELLnTEC is a pioneering developer of human and animal component-free precision media enabling scientists to successfully traverse the basic to translational research continuum and establish clinical applications. Join us as we lift the curtain on our two novel innovations:  achieve remarkable longevity of epithelial cells with our next-generation media featuring survival of human keratinocytes up to 90 population doublings!  create more complex organotypic 3D models of the epidermis by including melanocytes.
Discover how to take your research to new heights with CELLnTEC’s signature products:  fully defined media to minimize barriers to clinical applications and prevent late-stage failures.  precision media for developing sophisticated, reliable, and reproducible 2D/3D in vitro cell models.  specialized functional media to recapitulate the in vivo environment.  Higher Certified media to seamlessly transition from cell-based therapy development to clinical trials.

6:45 PM – 7:00 PM | Introducing the novel Electrospider series, a significant step towards the practical implementation of multiscale and multimaterial bioprinting.

Sponsored by: Bio3D Printing
Speaker: Dr. Alessandro Velletri

Bioprinting has made remarkable progress in the fabrication of functional tissues and organ constructs, ushering in a new era of personalized medicine with applications in transplantation, drug testing, research investigation, and disease modeling. Bio3DPrinting has taken a significant step towards its clinical translation by introducing Electrospider, a bioprinting ecosystem engineered for versatile multiscale and multimaterial biofabrication. The alignment of this technology with Bio3DPrinting’s core values of flexibility, adaptability, and pursuit of state-of-the-art solutions, is evident in the development of a new product series that adheres to regulations and standard for safety and manufacturing. Pushing the boundaries of technological advancement, the incorporation of a pioneering multi-tool printhead into the novel Electrospider series marks a transformative leap forward. The novel multi-tool printhead enables synergistic use of multiple bioprinting techniques within a single printing session. This new capability, coupled with advanced management software, ensures the highest quality and safety standards in bioprinting heterogenous tissue-like constructs. Consequently, this expansion paves the way for enhanced customization and innovation in tissue engineering and allied fields.

7:05 PM – 7:20 PM | Empowering Healthcare Research with the First-Ever, Turnkey rhCollagen Bioprinting Solution

Sponsored by: B9Creations
Speaker: B9Creations CEO Shon Anderson

Join us to learn about the breakthrough development in breast implant production using CollPlant’s human Type I collagen (rhCollagen) bioink plus B9Creations customized 3D printing platforms that has delivered parts currently undergoing large animal trials and enabling organ-on-a-chip applications. Plus discover the brand-new bio-production solution launching at TERMIS! CollPlant and B9Creations aim to revolutionize healthcare by introducing the first proven, off-the-shelf bioprinting offer combining CollPlant’s bioink and B9Creations’ printing and software toolset to enable research and bring patient-specific regenerative medicine to life. CollPlant’s plant-based bioink boasts the only commercially viable rhCollagen, which is identical to the collagen produced by the human body and does not elicit immune response that would cause implant rejection. Paired with B9Creations hardware and software additive manufacturing suite, this solution offers superior performance, consistency, safety, and ultimately better patient outcomes.